<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796549</url>
  </required_header>
  <id_info>
    <org_study_id>1200.40</org_study_id>
    <secondary_id>2008-001264-37</secondary_id>
    <nct_id>NCT00796549</nct_id>
  </id_info>
  <brief_title>BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients</brief_title>
  <official_title>A Phase II Single-arm Trial of BIBW 2992 in EGFR FISH Positive Non-small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this open-label, single arm Phase II trial is to explore the
      efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the
      RECIST criteria in patients with EGFR FISH positive advanced NSCLC Stage IIIB or IV,
      selected according to the following scheme:

        -  Forty (40) 1st line patients

        -  Thirty (30) 2nd line patients Patients entered into the trial will be treated and
           followed until death or lost to follow-up. Additional information will be obtained on
           the safety profile and PK analysis of BIBW 2992.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Best Objective Response</measure>
    <time_frame>Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Response (OR) Categorized by Time</measure>
    <time_frame>Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative number of participants with objective response by time points with responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Confirmed Objective Response (OR)</measure>
    <time_frame>Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of confirmed Objective Response is measured from the time of first Objective Response (OR) to the time of progression or death (or date of censoring for progression free survival).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control (DC)</measure>
    <time_frame>Every 8 weeks until last response assessment 28NOV12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with Objective response (OR) or stable disease (SD) as determined by RECIST version 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Confirmed Disease Control</measure>
    <time_frame>Every 8 weeks until last response assessment 28NOV12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of Disease Control is measured from the time of first Objective Response to the time of progression or death (or date of censoring for progression free survival) or respectively for SD as the time from date of randomization to date that disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Time</measure>
    <time_frame>Every 8 weeks until last response assessment 28NOV12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression Free Survival time defined as time from the start of treatment to the earliest of progression (RECIST), clinical progression (investigator), start of new anti-cancer treatment or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Time</measure>
    <time_frame>Baseline until last vital status assessment 17JUN13</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival time is defined as time from the date of start of treatment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15)</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Relevant Finding in Gastrointestinal and Skin Disorder</measure>
    <time_frame>First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The safety of patients was overall assessed in terms of adverse events (AEs), graded according to US NCI CTCAE version 3.0 [R04-0474], including skin reactions and gastrointestinal AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Relevant Findings in Laboratory Safety Parameters, Vital Signs and Left Ventricular Ejection Fraction</measure>
    <time_frame>First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with clinical relevant findings in Laboratory safety parameters, vital signs and Left ventricular ejection fraction . Relevant findings or worsenings of baseline conditions were reported as Adverse Events.
There were no clinically relevant finding reported for Vital signs and Left ventricular ejection fraction (LVEF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>End Of Treatment, up until 190 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Performance status assessed according to Eastern Cooperative Oncology Group (ECOG) performance status based on categories defined below :
0 : Fully active, able to carry on all pre-disease performance without restriction.
: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
: Dead.
Note: The ECOG scores presented are assessed at the end of treatment not at baseline, hence the patients having ECOGs&gt;2 are included.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>BIBW 2992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBW 2992 in EGFR FISH positive NSCLC patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BiBW 2992</intervention_name>
    <description>BIBW 2992 in EGFR FISH positive NSCLC patients</description>
    <arm_group_label>BIBW 2992</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients aged &gt;18 years.

          2. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural
             effusion) or Stage IV and histopathological classification of adeno- or
             bronchoalveolar carcinoma (BAC).

          3. Increased EGFR gene copy number assessed by FISH analysis. After signed informed
             consent, positive result to EGFR FISH determination is mandatory to proceed to other
             screening assessments.

          4. At least one tumour lesion that can accurately be measured by computed tomography
             (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest
             diameter to be recorded as more or same 20 mm using conventional techniques or moro
             or same 10 mm with spiral CT scan.

          5. Patients not previously exposed to chemotherapy for NSCLC (1st line patients, 40 in
             total; for these subjects adjuvant chemotherapy is allowed if at least 12 months
             elapsed since last course of treatment), or patients with relapse after one systemic
             treatment (2nd line patients, 30 in total; if less than 12 months elapsed since
             adjuvant chemotherapy, patients are 2nd line ones, as adjuvant chemotherapy must be
             considered a line of treatment).

          6. Life expectancy of at least three (3) months.

          7. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0, 1 or 2.

          8. Written informed consent that is consistent with ICH-GCP guidelines.

        Exclusion criteria:

          1. More than two (2) prior cytotoxic chemotherapy treatment regimens for relapsed or
             metastatic NSCLC, included adjuvant chemotherapy if relapse occurred less than 12
             months before

          2. Previous treatment with erlotinib (Tarceva®), gefitinib (Iressa®) or any other EGFR
             inhibiting small molecule or antibody.

          3. Active brain metastases (stable &lt;4 weeks, symptomatic, requiring treatment with
             anticonvulsants, or leptomeningeal disease). Dexamethasone therapy will be allowed if
             administered as a stable dose for at least one month before randomization.

          4. Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance
             non-cancer therapy) or immunotherapy within the past 4 weeks before first drug
             administration.

          5. Significant or recent acute gastrointestinal disorders with diarrhea as a major
             symptom e.g., Crohn disease, malabsorption, or CTCAE Grade &gt;2 diarrhea of any
             etiology at baseline

          6. Patients who have any other life-threatening illness or organ system dysfunction
             which, in the opinion of the investigator, would either compromise patient safety or
             interfere with the evaluation of the safety of the test drug.

          7. Other malignancies diagnosed within the past five (5) years (other than non
             melanomatous skin cancer and in situ cervical cancer).

          8. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.

          9. Patients with any serious active infection (i.e., requiring an IV antibiotic,
             antifungal, or antiviral agents).

         10. Patients with known HIV, active hepatitis B or active hepatitis C.

         11. Known or suspected active drug or alcohol abuse.

         12. Women of child-bearing potential or men who are able to father a child unwilling to
             use a medically acceptable method of contraception during the trial.

         13. Pregnancy or breast feeding.

         14. Patients unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.40.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aviano (PN)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Faenza (RA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Livorno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugo (RA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.40.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1200/1200.40_Literature.pdf</url>
  </link>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 21, 2014</lastchanged_date>
  <firstreceived_date>November 21, 2008</firstreceived_date>
  <firstreceived_results_date>August 8, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled on December 23rd 2008 . Last patient enrolled on September 1st 2011. Patients were recruited in Oncology departments of Italian investigational sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Afatinib 50mg</title>
          <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218">Excluding duplicate records for 5 patients who were screened twice</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered</title>
              <participants_list>
                <participants group_id="P1" count="69">entered and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not entered</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Afatinib 50mg</title>
          <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.8" spread="11.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Objective Response</title>
        <description>Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0.</description>
        <time_frame>Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS). TS consisted of all patients who were dispensed study medication and have taken at least 1 dose of Afatinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Best Objective Response</title>
            <description>Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13.0" lower_limit="6.1" upper_limit="23.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Objective Response (OR) Categorized by Time</title>
        <description>Cumulative number of participants with objective response by time points with responders.</description>
        <time_frame>Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Objective Response (OR) Categorized by Time</title>
            <description>Cumulative number of participants with objective response by time points with responders.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>by week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>by week 96</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Confirmed Objective Response (OR)</title>
        <description>Duration of confirmed Objective Response is measured from the time of first Objective Response (OR) to the time of progression or death (or date of censoring for progression free survival).</description>
        <time_frame>Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Confirmed Objective Response (OR)</title>
            <description>Duration of confirmed Objective Response is measured from the time of first Objective Response (OR) to the time of progression or death (or date of censoring for progression free survival).</description>
            <units>Weeks</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45.5" spread="36.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Control (DC)</title>
        <description>Percentage of participants with Objective response (OR) or stable disease (SD) as determined by RECIST version 1.0.</description>
        <time_frame>Every 8 weeks until last response assessment 28NOV12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Disease Control (DC)</title>
            <description>Percentage of participants with Objective response (OR) or stable disease (SD) as determined by RECIST version 1.0.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50.7" lower_limit="38.4" upper_limit="63.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Confirmed Disease Control</title>
        <description>Duration of Disease Control is measured from the time of first Objective Response to the time of progression or death (or date of censoring for progression free survival) or respectively for SD as the time from date of randomization to date that disease progression.</description>
        <time_frame>Every 8 weeks until last response assessment 28NOV12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Confirmed Disease Control</title>
            <description>Duration of Disease Control is measured from the time of first Objective Response to the time of progression or death (or date of censoring for progression free survival) or respectively for SD as the time from date of randomization to date that disease progression.</description>
            <units>Weeks</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.4" spread="35.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) Time</title>
        <description>Progression Free Survival time defined as time from the start of treatment to the earliest of progression (RECIST), clinical progression (investigator), start of new anti-cancer treatment or death.</description>
        <time_frame>Every 8 weeks until last response assessment 28NOV12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival (PFS) Time</title>
            <description>Progression Free Survival time defined as time from the start of treatment to the earliest of progression (RECIST), clinical progression (investigator), start of new anti-cancer treatment or death.</description>
            <units>Weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.43" lower_limit="7.43" upper_limit="15.71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Time</title>
        <description>Overall survival time is defined as time from the date of start of treatment to the date of death.</description>
        <time_frame>Baseline until last vital status assessment 17JUN13</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival (OS) Time</title>
            <description>Overall survival time is defined as time from the date of start of treatment to the date of death.</description>
            <units>Weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50.43" lower_limit="33.43" upper_limit="64.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15)</title>
        <description>Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15.</description>
        <time_frame>Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic set (PK set) contains all patients who received study medication and have evaluable pharmacokinetic parameter data.
Data from patients who received the starting dose of 50 mg afatinib and were still on treatment and not dose-reduced on Day 15 are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg 1st Line</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors). Only Patients with 1st line anti cancer treatment, indicating that they had not received prior treatment with chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib 50mg 2nd Line</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors). Only Patients with 2nd line anti cancer treatment, indicating that they had received one prior anti cancer treatment with chemotherapy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15)</title>
            <description>Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15.</description>
            <units>ng/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.9" spread="64.5"/>
                  <measurement group_id="O2" value="29.7" spread="61.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Relevant Finding in Gastrointestinal and Skin Disorder</title>
        <description>The safety of patients was overall assessed in terms of adverse events (AEs), graded according to US NCI CTCAE version 3.0 [R04-0474], including skin reactions and gastrointestinal AEs.</description>
        <time_frame>First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated Set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Clinical Relevant Finding in Gastrointestinal and Skin Disorder</title>
            <description>The safety of patients was overall assessed in terms of adverse events (AEs), graded according to US NCI CTCAE version 3.0 [R04-0474], including skin reactions and gastrointestinal AEs.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Diarrhoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stomatitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal pain upper</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cheilitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspepsia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dysphagia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal distension</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dry mouth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flatulence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastritis erosive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Odynophagia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rectal haemorrahage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tongue Ulceration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Skin exfoliation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dry skin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nail disorder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pruritus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dermatitis acneiform</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alopecia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Granuloma skin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hirsutism</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypertrichosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nail discolouration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Night sweats</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Skin fissures</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Skin reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Relevant Findings in Laboratory Safety Parameters, Vital Signs and Left Ventricular Ejection Fraction</title>
        <description>Number of participants with clinical relevant findings in Laboratory safety parameters, vital signs and Left ventricular ejection fraction . Relevant findings or worsenings of baseline conditions were reported as Adverse Events.
There were no clinically relevant finding reported for Vital signs and Left ventricular ejection fraction (LVEF).</description>
        <time_frame>First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated Set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Clinical Relevant Findings in Laboratory Safety Parameters, Vital Signs and Left Ventricular Ejection Fraction</title>
            <description>Number of participants with clinical relevant findings in Laboratory safety parameters, vital signs and Left ventricular ejection fraction . Relevant findings or worsenings of baseline conditions were reported as Adverse Events.
There were no clinically relevant finding reported for Vital signs and Left ventricular ejection fraction (LVEF).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood bilirubin increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Creatine phosphokinase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ejection fraction decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>International normalised ratio increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Transaminases increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weight decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
        <description>Performance status assessed according to Eastern Cooperative Oncology Group (ECOG) performance status based on categories defined below :
0 : Fully active, able to carry on all pre-disease performance without restriction.
: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
: Dead.
Note: The ECOG scores presented are assessed at the end of treatment not at baseline, hence the patients having ECOGs&gt;2 are included.</description>
        <time_frame>End Of Treatment, up until 190 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set (TS).</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib 50mg</title>
            <description>Afatinib 50mg film coated tablets was administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
            <description>Performance status assessed according to Eastern Cooperative Oncology Group (ECOG) performance status based on categories defined below :
0 : Fully active, able to carry on all pre-disease performance without restriction.
: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
: Dead.
Note: The ECOG scores presented are assessed at the end of treatment not at baseline, hence the patients having ECOGs&gt;2 are included.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Afatinib 50mg</title>
          <description>Afatinib 50mg film coated tablets where administered once daily as long as they were tolerated by patients, until a disease progression (according to the response evaluation criteria in solid tumors)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
